<DOC>
	<DOCNO>NCT01831024</DOCNO>
	<brief_summary>The efficacy safety Dignicap System prevent chemotherapy induce alopecia evaluate woman early breast cancer undergo adjuvant neoadjuvant chemotherapy regimen . The scalp cold cap apply chemotherapy cycle . Hair loss evaluate patient self assessment 5 standardized photograph take prior chemotherapy cycle . A concurrent control group use cold cap also evaluate .</brief_summary>
	<brief_title>Efficacy Safety Dignicap System Preventing Chemotherapy Induced Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Female patient &gt; /= 18 year age Documented diagnosis stage I II breast cancer A plan course chemotherapy adjuvant neoadjuvant set curative intent include one follow regimen : Doxorubicin 60 mg/m2 cyclophosphamide 600 mg/m2 x 4 6 cycle IV every 2 3 week Docetaxel 75 mg/m2 cyclophosphamide 600 mg/m2 x 4 6 cycle IV every 3 week Paclitaxel 80 mg/m2 weekly IV x least 12 week without IV trastuzumab Paclitaxel 175 mg/m2 IV every 2 week x 4 6 cycle ( without anthracycline ) Paclitaxel weekly carboplatin AUC 2 weekly AUC 6 every 3 week IV x 4 6 cycle trastuzumab IV weekly every 3 week Docetaxel 75 mg/m2 carboplatin AUC 6 IV every 3 week x 4 6 cycle trastuzumab IV weekly every 3 week Targeted agent trastuzumab lapatinib allow Plan complete chemotherapy within 6 month At least two year last chemotherapy cause hair loss complete recovery hair Karnofsky performance status &gt; /= 80 % Willing able sign inform consent protocol treatment Willing participate study procedure include photograph head first cycle chemotherapy 1 month last chemotherapy Willing enroll extension protocol follow 5 year follow end chemotherapy treatment Patients female pattern baldness resemble picture I3 high Savin scale Autoimmune disease affect hair ; e.g . alopecia areata , systemic lupus associate hair loss A history whole brain radiation Plans use chemotherapy regimen specify inclusion criterion . Specifically , patient receive regimen include anthracycline taxane eligible trial ( AC/T , EC/T , TAC , etc . ) Concurrent hormone therapy chemotherapy . Hormone therapy use indicate follow completion chemotherapy Underlying clinically significant liver disease include active viral hepatitis abnormal liver function test &gt; 1.5 time upper limit normal , include alkaline phosphatase , AST , total bilirubin . Patients Gilbert´s disease ( elevated indirect bilirubin ) eligible participation . Clinically significant renal dysfunction define serum creatinine &gt; upper limit normal . A serious concurrent infection medical illness would jeopardize ability patient complete plan therapy followup A history persistent grade 2 ( high ) alopecia induce prior chemotherapeutic regimen Participation clinical investigation exposure investigational agent , drug , device procedure may cause hair loss Intercurrent lifethreatening malignancy A history cold agglutinin disease cryoglobulinemia . Evidence untreated poorly control hyper hypothyroidism A history silicon allergy American Society Anesthesiologist Class ≥3</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cold cap</keyword>
	<keyword>Scalp cooling</keyword>
	<keyword>Chemotherapy induce alopecia</keyword>
	<keyword>Breast cancer</keyword>
</DOC>